Nerviano Medical Sciences (NervianoMS)
About Nerviano Medical Sciences (NervianoMS)
NMS Group is the largest Italian company committed in innovation and research and development in oncology. With 450 total employees, NMS Group employs over 200 qualified researchers involved in research and development, from 'target validation' to phase II clinical trials.The discovery and applied research of Nerviano Medical Sciences
- representing the innovative heart of the Group and make it an important and international reference in the field of personalized therapy
- integrate with other development activities of a new drug.
NMS Group is, in fact, the only reality in Italy able to manage the entire integrated chain of the research and development path: from pre-clinical phase of research, to First-Time-In-Man of clinical phase, up to production and packaging of the finished drug.
NMS also provides services of Research and Production addressed to local and international markets through three different companies: Accelera, one of the few companies engaged in preclinical research in Italy; Clioss engaged in clinical development starting from First-Time-In-Man and Nerpharma, dealing with activities from formulation to production of the active principle.
24 articles about Nerviano Medical Sciences (NervianoMS)
-
Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate
12/14/2023
Nerviano Medical Sciences S.r.l., a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A., a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate.
-
Nerviano Medical Sciences Announces Enhanced US Executive Team
8/1/2023
Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the expansion of and transition in its executive team of its wholly owned U.S. subsidiary (Nerviano Medical Sciences, Inc./ NMS-US) in Boston.
-
Nerviano Medical Sciences Announces Licensing of Linker-Payload Technology to Solve Therapeutics to Develop and Commercialize Novel Antibody-Drug Conjugates.
6/5/2023
Nerviano Medical Sciences S.r.l. (NMS) announced signing of a license agreement and right of option with Solve Therapeutics, Inc. (SolveTx) to develop and commercialize novel antibody-drug conjugates (ADCs) for up to four cancer targets selected by SolveTx.
-
Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset
1/13/2023
Nerviano Medical Sciences S.r.l. announced the senior appointment to drive validation and maximize the value of its IDH1/IDH2 Inhibitor Asset, NMS-173, and facilitate its expanding and advancing clinical pipeline.
-
Celltrion agreed Wednesday to jointly develop Abpro’s cancer molecule ABP-102 in a deal that could net as much as $1.75 billion. See inside for more cancer collaborations.
-
Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck
9/21/2022
Nerviano Medical Sciences S.r.l. announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293.
-
Nerviano Medical Sciences Announces Collaboration and License Agreement with Merck to Discover Small Molecule Inhibitors of Certain Anticancer Targets
6/1/2018
The two companies will collaborate on the discovery of small molecule inhibitors for development as anticancer agents.
-
The parts expect the closing in the first quarter 2018.
-
TrovaGene And Nerviano Medical Sciences Announce License Agreement For Therapeutic Candidate PCM-075
3/16/2017
-
Nerviano Medical Sciences (NervianoMS) Presents Data Regarding A Potent New Cytotoxic Molecule For ADC Generation
10/20/2016
-
Oxford BioTherapeutics Licenses Nerviano Medical Sciences (NervianoMS)' Drug-Linker Technology To Develop Novel Antibody Drug Conjugates
4/4/2016
-
Tiziana Life Sciences Plc Licenses Milciclib From Nerviano Medical Sciences (NervianoMS)
1/20/2015
-
Ignyta Announces Amendment To License Agreement With Nerviano Medical Sciences (NervianoMS)
12/15/2014
-
Ignyta And Nerviano Medical Sciences (NervianoMS) Announce License Agreement For Two First-in-Class Kinase Inhibitors
8/5/2014
-
Cellectis And Accelera (Nerviano Medical Sciences (NervianoMS)) Sign An Agreement To Complete Preclinical Studies Of Cellectis’ Lead Product Candidate UCART19
6/5/2014
-
Nerviano Medical Sciences (NervianoMS) and Servier Announce a Collaboration and License Agreement for a Novel Anticancer Drug
7/30/2013
-
Professor Carlo Maria Croce Joins the Board of Nerviano Medical Sciences (NervianoMS)
10/26/2011
-
Nerviano Medical Sciences (NervianoMS) Announces New License Agreement
3/15/2011
-
Nerviano Medical Sciences (NervianoMS) Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
5/13/2009
-
ChemDiv, Inc. Successful Milestone In Lead Discovery Collaboration With Nerviano Medical Sciences (NervianoMS)
3/2/2009